Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TranS1 targets $80.5m from IPO

This article was originally published in Clinica

Executive Summary

Minimally-invasive spinal surgery specialist TranS1 aims to raise $80.5m via flotation on the Nasdaq stock exchange. The Wilmington, North Carolina-based company, which filed for registration with the US Securities and Exchange Commission last week (July 24), plans to use the funds to further the development of its AxiaLIF (axial lumbar interbody fusion) product, as well as its disc replacement and prosthetic disc nucleus technologies. The company may also use some of the IPO proceeds to alleviate its financial shortcomings. TranS1 recorded a net loss of $9.5m for fiscal 2006, and in the first quarter of 2007, ending March 31, it lost $1.7m (an improvement of 7% on the same time period for the previous year).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel